1. Session 4 - Efficacy and Risk Assessment
  2. Efficacy requirements for preservative PTs, especially PT 5

    David Ashworth David Ashworth
    Managing Director, Klarus Consulting Ltd, UK
  3. Biocide active substance/product assessment; approaches and issues: Experiences with PT 19 (repellents) and PT2/3/4 (disinfectants)

    • Experience dealing with the various aspects of preparing a submission to ECHA
    • Issues with efficacy and rates of use
    • Toxicology and defining suitable endpoints
    • Design of specific studies
    • Approaches to preparing Exposure assessments and sources of data
    Scott Samuels Scott Samuels
    Principal Consultant – Human Safety: Toxicologist, ERM
  4. Q&A

  5. Refreshments

  6. Session 5 - The Impact of BPR on Downstream Users
  7. Biocides and electronics

    Alex Paul Alex Paul
    Principal: Chemical Regulatory Services, Yordas Group, UK
  8. How a retailer deals with biocides requirements and alternatives

    • Status from all European Coops
    • Use of biocides in transportation
    • Requirements for daily use products
    Malene Teller Blume Malene Teller Blume
    Quality Manager, Coop Danmark
  9. Q&A

  10. Lunch

  11. Session 6 - The need for and approaches to developing new biocides
  12. Biocides and innovation

    • BPR aim of development of safer alternatives
    • How is innovation possible in the biocides market?
    • Examples from different biocides market segments
    Nathalie Hanon Nathalie Hanon
    Executive Vice President & Head of Biocides, CEHTRA
  13. The Danish EPA project for alternatives for wood protection or biocidal products used in construction

    • Challenges with traditional wood preservatives
    • Leaching of active substances to the environment
    • Emerging alternative techniques
    Nina Falk Gregersen Nina Falk Gregersen
    Scientific Officer, Environmental Protection Agency, Denmark
  14. Triple challenge: timing/content/cost - an SME perspective on BPR

    • How we deal at present with diversified regulations throughout EU
    • How we intend to deal with BPR and our portfolio
    • The (un)known pitfalls
    • General thoughts of and suggestions for BPR by an SME
    Rik Daneels Rik Daneels
    Managing Partner, Aqua Ecologic, Belgium
  15. Q&A

  16. Refreshments

  17. Session 7 - Legal/regulatory issues
  18. BPR related cases - view from inside the Board of Appeal

    • Board of Appeal’s assessment of every effort
    • Contractual freedom in data sharing negotiations
    • Cost sharing discussions as part of the data sharing negotiations
    Sari Haukka Sari Haukka
    Legally Qualified Member of the ECHA Board of Appeal, ECHA
  19. The Board of Appeal – an advocate’s view

    • Issues raised before the BoA but not yet answered
    • The role of national courts in data sharing
    • Personal perspectives from an advocate before the BoA
    Darren Abrahams Darren Abrahams
    Partner, Barrister & Avocat, Steptoe International (UK) LLP
  20. The new scientific criteria for identifying endocrine disruptors: practical implications

    • Regulatory background and the new scientific criteria
    • The ED guidance document: drafting, testing, critique
    • Implications for substance approval and product authorisation
    Glenn Lurman Glenn Lurman
    Scientist, German Federal Institute for Risk Assessment (BfR)
  21. The impact of Brexit

    • Product regulation
    • R&D
    • Funding
    • Intellectual property
    • Competition
    • Cross-border trade
    • Data privacy
    Gunnar Sachs Gunnar Sachs
    Lawyer, Maître en droit (Paris), Expert Lawyer for Intellectual Property Law, Clifford Chance
  22. Q&A

  23. Close of conference

View previous day

/ next day